Juliana I. Delgado
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Juliana I. Delgado has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Afsar Barlas
Molecular Cytology Core, Memorial Sloan Kettering Cancer Center, New York, New York
45 shared publications - Aimee M. Crago
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
45 shared publications - Allison L. Richards
Memorial Sloan Kettering Cancer Center 2 Marie-Josée and Henry R. Kravis Center for Molecular Oncology New York, New York
45 shared publications - Andrew Koff
Memorial Sloan Kettering Cancer Center
45 shared publications - Babak Joseph Mehrara
Plastic and Reconstructive Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
45 shared publications - Caroline E. Gleason
Louis V. Gerstner Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, New York
45 shared publications
Latest Publications
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Dose reductions in this study identified by individual patients
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Dose reductions in this study identified by individual patients
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Transcript changes relative to quiescence
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Transcript changes relative to quiescence
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Enforced expression of ANGPTL4 can induce stable growth arrest and SASP gene expression in A549 cells treated with palbociclib
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Enforced expression of ANGPTL4 can induce stable growth arrest and SASP gene expression in A549 cells treated with palbociclib
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Increases in ANGPTL4 are not associated with palbociclib induced senescence in ER+ breast cancer cell lines
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Increases in ANGPTL4 are not associated with palbociclib induced senescence in ER+ breast cancer cell lines
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Enforced expression of ANGPTL4 can induce stable growth arrest and SASP gene expression in A549 cells treated with palbociclib
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Enforced expression of ANGPTL4 can induce stable growth arrest and SASP gene expression in A549 cells treated with palbociclib
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Patient toxicities graded according to the National Cancer Institute's common terminology criteria for adverse events, version 4.0
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Patient toxicities graded according to the National Cancer Institute's common terminology criteria for adverse events, version 4.0
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Metabolome profiles of LS8817tetONFMDM2 undergoing cell cycle exit and geroconversion
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Metabolome profiles of LS8817tetONFMDM2 undergoing cell cycle exit and geroconversion
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Dose reductions in this study identified by individual patients
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Dose reductions in this study identified by individual patients
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S16 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Relationship between CDH18 expression, MDM2 downregulation, and ANGPTL4 mRNA expression in patients treated with abemaciclib
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S16 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Relationship between CDH18 expression, MDM2 downregulation, and ANGPTL4 mRNA expression in patients treated with abemaciclib
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Demographics of patients enrolled in phase II clinical trial of abemaciclib in dedifferentiated liposarcoma
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Demographics of patients enrolled in phase II clinical trial of abemaciclib in dedifferentiated liposarcoma